This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Iovance Biotherapeutics’s 8K filing here.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Read More
- Five stocks we like better than Iovance Biotherapeutics
- What is Put Option Volume?
- 3 Mining Stocks Poised to Ride the Precious Metals Boom
- What is the Australian Securities Exchange (ASX)
- Cybersecurity Stocks Are Soaring—Here’s Why These 3 Stand Out
- How to Profit From Growth Investing
- 2 Stocks to Shield Your Portfolio from AI and Tech Froth
